Alcon Inc (ALC)
85.57
+0.07
(+0.08%)
USD |
NYSE |
Nov 21, 16:00
85.53
-0.04
(-0.05%)
After-Hours: 20:00
Alcon Enterprise Value: 45.64B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 45.64B |
| November 20, 2024 | 45.60B |
| November 19, 2024 | 45.57B |
| November 18, 2024 | 45.76B |
| November 15, 2024 | 45.42B |
| November 14, 2024 | 45.44B |
| November 13, 2024 | 46.59B |
| November 12, 2024 | 46.29B |
| November 11, 2024 | 48.96B |
| November 08, 2024 | 49.12B |
| November 07, 2024 | 49.11B |
| November 06, 2024 | 48.56B |
| November 05, 2024 | 49.03B |
| November 04, 2024 | 48.90B |
| November 01, 2024 | 48.71B |
| October 31, 2024 | 48.79B |
| October 30, 2024 | 49.45B |
| October 29, 2024 | 50.06B |
| October 28, 2024 | 50.24B |
| October 25, 2024 | 49.93B |
| October 24, 2024 | 50.00B |
| October 23, 2024 | 50.06B |
| October 22, 2024 | 50.12B |
| October 21, 2024 | 49.97B |
| October 18, 2024 | 50.37B |
| Date | Value |
|---|---|
| October 17, 2024 | 50.06B |
| October 16, 2024 | 50.44B |
| October 15, 2024 | 51.10B |
| October 14, 2024 | 51.39B |
| October 11, 2024 | 51.14B |
| October 10, 2024 | 50.96B |
| October 09, 2024 | 51.01B |
| October 08, 2024 | 50.75B |
| October 07, 2024 | 50.51B |
| October 04, 2024 | 51.42B |
| October 03, 2024 | 51.84B |
| October 02, 2024 | 52.34B |
| October 01, 2024 | 52.34B |
| September 30, 2024 | 52.81B |
| September 27, 2024 | 52.46B |
| September 26, 2024 | 52.18B |
| September 25, 2024 | 52.03B |
| September 24, 2024 | 51.83B |
| September 23, 2024 | 51.64B |
| September 20, 2024 | 51.40B |
| September 19, 2024 | 51.81B |
| September 18, 2024 | 50.99B |
| September 17, 2024 | 51.24B |
| September 16, 2024 | 51.96B |
| September 13, 2024 | 51.90B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
22.07B
Minimum
Mar 23 2020
53.01B
Maximum
Sep 12 2024
38.86B
Average
39.02B
Median
Dec 07 2023
Enterprise Value Benchmarks
| AC Immune SA | 137.84M |
| CRISPR Therapeutics AG | 2.015B |
| Addex Therapeutics Ltd | 4.450M |
| NLS Pharmaceutics Ltd | 14.00M |
| Molecular Partners AG | 28.94M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 263.00M |
| Revenue (Quarterly) | 2.454B |
| Total Expenses (Quarterly) | 2.122B |
| EPS Diluted (Quarterly) | 0.53 |
| Gross Profit Margin (Quarterly) | 55.87% |
| Profit Margin (Quarterly) | 10.72% |
| Earnings Yield | 2.73% |
| Operating Earnings Yield | 2.88% |
| Normalized Earnings Yield | 2.735 |